Carcinogenesis Advance Access originally published online on September 8, 2005
Carcinogenesis 2005 26(12):2031-2045; doi:10.1093/carcin/bgi223
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REVIEW |
Tumor suppressor genetics
Fred Hutchinson Cancer Research Center, C1-015, 1100 Fairview Avenue N, PO Box 19024, Seattle, WA 90109, USA
* To whom correspondence should be addressed. Email: cjkemp{at}fhcrc.org
The observation that mutations in tumor suppressor genes can have haploinsufficient, as well as gain of function and dominant negative, phenotypes has caused a reevaluation of the ‘two-hit’ model of tumor suppressor inactivation. Here we examine the history of haploinsufficiency and tumor suppressors in order to understand the origin of the ‘two-hit’ dogma. The two-hit model of tumor suppressor gene inactivation was derived from mathematical modeling of cancer incidence. Subsequent interpretations implied that tumor suppressors were recessive, requiring mutations in both alleles. This model has provided a useful conceptual framework for three decades of research on the genetics and biology of tumor suppressor genes. Recently it has become clear that mutations in tumor suppressor genes are not always completely recessive. Haploinsufficiency occurs when one allele is insufficient to confer the full functionality produced from two wild-type alleles. Haploinsufficiency, however, is not an absolute property. It can be partial or complete and can vary depending on tissue type, other epistatic interactions, and environmental factors. In addition to simple quantitative differences (one allele versus two alleles), gene mutations can have qualitative differences, creating gain of function or dominant negative effects that can be difficult to distinguish from dosage-dependence. Like mutations in many other genes, tumor suppressor gene mutations can be haploinsufficient, dominant negative or gain of function in addition to recessive. Thus, under certain circumstances, one hit may be sufficient for inactivation. In addition, the phenotypic penetrance of these mutations can vary depending on the nature of the mutation itself, the genetic background, the tissue type, environmental factors and other variables. Incorporating these new findings into existing models of the clonal evolution will be a challenge for the future.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Liu, G. L. Borchert, S. P. Donald, B. A. Diwan, M. Anver, and J. M. Phang Proline Oxidase Functions as a Mitochondrial Tumor Suppressor in Human Cancers Cancer Res., August 15, 2009; 69(16): 6414 - 6422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Burzio, C. Villota, J. Villegas, E. Landerer, E. Boccardo, L. L. Villa, R. Martinez, C. Lopez, F. Gaete, V. Toro, et al. Expression of a family of noncoding mitochondrial RNAs distinguishes normal from cancer cells PNAS, June 9, 2009; 106(23): 9430 - 9434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Jiang, A. Dunbar, L. P. Gondek, S. Mohan, M. Rataul, C. O'Keefe, M. Sekeres, Y. Saunthararajah, and J. P. Maciejewski Aberrant DNA methylation is a dominant mechanism in MDS progression to AML Blood, February 5, 2009; 113(6): 1315 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Su, H. Cao, S. Tan, Y. Huang, X. Jia, L. Jiang, K. Wang, Y. Chen, J. Long, X. Liu, et al. Toxicology Profiles of a Novel p53-Armed Replication-Competent Oncolytic Adenovirus in Rodents, Felids, and Nonhuman Primates Toxicol. Sci., November 1, 2008; 106(1): 242 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tada, F. Kanai, Y. Tanaka, K. Tateishi, M. Ohta, Y. Asaoka, M. Seto, R. Muroyama, K. Fukai, F. Imazeki, et al. Down-Regulation of Hedgehog-Interacting Protein through Genetic and Epigenetic Alterations in Human Hepatocellular Carcinoma Clin. Cancer Res., June 15, 2008; 14(12): 3768 - 3776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Y. Park, H. Sakamoto, S. D. Kirley, S. Ogino, T. Kawasaki, E. Kwon, M. Mino-Kenudson, G. Y. Lauwers, D. C. Chung, B. R. Rueda, et al. The Cables Gene on Chromosome 18q Is Silenced by Promoter Hypermethylation and Allelic Loss in Human Colorectal Cancer Am. J. Pathol., November 1, 2007; 171(5): 1509 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Itoh, S. Iwashita, M. B. Cohen, D. K. Meyerholz, and S. Linn Ddb2 is a haploinsufficient tumor suppressor and controls spontaneous germ cell apoptosis Hum. Mol. Genet., July 1, 2007; 16(13): 1578 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Heaphy, W. C. Hines, K. S. Butler, C. M. Haaland, G. Heywood, E. G. Fischer, M. Bisoffi, and J. K. Griffith Assessment of the Frequency of Allelic Imbalance in Human Tissue Using a Multiplex Polymerase Chain Reaction System J. Mol. Diagn., April 1, 2007; 9(2): 266 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lin, M. Czapiga, L. Nini, J.-H. Zhang, and W. F. Simonds Nuclear Localization of the Parafibromin Tumor Suppressor Protein Implicated in the Hyperparathyroidism-Jaw Tumor Syndrome Enhances Its Proapoptotic Function Mol. Cancer Res., February 1, 2007; 5(2): 183 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Williams, D. Choong, S. A. Johnson, and I. G. Campbell Genetic and Epigenetic Analysis of CHEK2 in Sporadic Breast, Colon, and Ovarian Cancers Clin. Cancer Res., December 1, 2006; 12(23): 6967 - 6972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Eddy and N. Maizels Gene function correlates with potential for G4 DNA formation in the human genome Nucleic Acids Res., September 1, 2006; 34(14): 3887 - 3896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-M. Chien, S. Rabin, E. Macias, P. L. Miliani de Marval, K. Garrison, J. Orthel, M. Rodriguez-Puebla, and M. L. Fero Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1. PNAS, March 14, 2006; 103(11): 4122 - 4127. [Abstract] [Full Text] [PDF]
|
|